BG Growth Series – Avantium
BG Growth Series – Avantium
Welcome to the “BG Growth Series“, where entrepreneurs share their inspiring stories, insights, and tips to navigate the path of innovation and growth.
In this episode, we feature Avantium, a pioneering commercial-stage company at the forefront of renewable and circular polymer materials. Avantium’s groundbreaking work in developing FDCA – the key building block for the 100% plant-based, recyclable, and degradable plastic PEF – is setting a new standard in sustainable alternatives to fossil-based plastics.
We had the opportunity to sit down with Avantium’s CEO, Tom van Aken, to explore their journey and ambitious vision for the future. With the world’s first commercial FDCA flagship plant now completed and paving the way for the commercialisation of PEF, Avantium has reached a critical milestone.
Over the past 3 years, Avantium was advised by Bryan, Garnier & Co in 3 different capital raisings amounting to EUR 126.2m. These transactions include a EUR 11.2 million Accelerated Bookbuild Offering in 2024, a EUR 70 million Rights Offering and Institutional Upsize ABB in 2024, following a EUR 45 million Follow-On Offering in 2022. In 2024, the launch of the world’s first commercial FDCA plant marked a significant milestone for Avantium, showcasing its progress in renewable, circular materials and paving the way for the large-scale production of its plant-based plastic, Releaf — a revolutionary material set to transform the plastic industry.
Watch this episode of the BG Growth Series to learn more about Avantium’s vision and their mission to redefine the future of sustainable plastics.
Get in touch
Whether you’re at the outset seeking funding, or an established firm searching for strategic options, our team will provide you with tailored advice to help you reach your goals.
All related deals:
Our transactions
Bryan, Garnier & Co offers a complete range of investment banking services, from growth financing to mergers and acquisitions.
About Bryan, Garnier & Co
Bryan, Garnier & Co is a European growth investment bank that helps healthcare and technology companies become global champions. By combining extensive sector expertise with an entrepreneurial mindset, Bryan Garnier provides companies and their investors with independent growth strategic advice, and privileged access to buyers and capital in Europe, the US and Asia.
As a full-service investment bank, the firm offering includes private and public growth financing solutions, mergers and acquisitions (M&A) advisory, research insights, and institutional sales & execution. Founded in 1996, Bryan Garnier & Co is an independent partnership with around 200 employees located in major financial centres in Europe and the US.